SUVENNSESuven Life Sciences Limited· PharmaceuticalsLowNeutral
Announced Wed, 12 Nov · 16:55 IST

Monitoring Agency Report for quarter ended September 30, 2025

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Suven Life Sciences Limited has filed the Monitoring Agency Report (MAR) for the quarter ended September 30, 2025, in line with SEBI's ICDR Regulations. This filing is a routine compliance requirement that applies to companies that have raised funds through a public issue, rights issue, or preferential allotment above prescribed thresholds. The report provides independent oversight on whether the proceeds raised are being used in line with the purposes disclosed to shareholders at the time of the issue. Specific details on the amount monitored, deployment status, and any deviations would be available in the full report submitted to the stock exchanges.

Likely market impact

This is primarily a procedural regulatory disclosure and is unlikely to materially move the stock price on its own. Investors should look at the full report to check whether the company's fund utilization is on track or if there are any material deviations from stated objectives, which could warrant closer scrutiny.